These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20358439)

  • 21. Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables.
    Cheng B; Chow SC; Burt D; Cosmatos D
    J Biopharm Stat; 2008; 18(3):494-501. PubMed ID: 18470758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences between study-specific and subject-specific heart rate corrections of the QT interval in investigations of drug induced QTc prolongation.
    Malik M; Hnatkova K; Batchvarov V
    Pacing Clin Electrophysiol; 2004 Jun; 27(6 Pt 1):791-800. PubMed ID: 15189536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sevoflurane causes greater QTc interval prolongation in elderly patients than in younger patients.
    Nakao S; Hatano K; Sumi C; Masuzawa M; Sakamoto S; Ikeda S; Shingu K
    Anesth Analg; 2010 Mar; 110(3):775-9. PubMed ID: 20185656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A nonparametric approach to QT interval correction for heart rate.
    Wang D; Cheung YB; Arezina R; Taubel J; Camm AJ
    J Biopharm Stat; 2010 May; 20(3):508-22. PubMed ID: 20358433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. QT analysis: a complex answer to a 'simple' problem.
    Li L; Desai M; Desta Z; Flockhart D
    Stat Med; 2004 Sep; 23(17):2625-43. PubMed ID: 15316947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statistical analysis methods for QT/QTc prolongation.
    Ma H; Smith B; Dmitrienko A
    J Biopharm Stat; 2008; 18(3):553-63. PubMed ID: 18470763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events.
    Molnar J; Zhang F; Weiss J; Ehlert FA; Rosenthal JE
    J Am Coll Cardiol; 1996 Jan; 27(1):76-83. PubMed ID: 8522713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance characteristics for some typical QT study designs under the ICH E-14 guidance.
    Hutmacher MM; Chapel S; Agin MA; Fleishaker JC; Lalonde RL
    J Clin Pharmacol; 2008 Feb; 48(2):215-24. PubMed ID: 18199896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed effects in the exposure-response analysis of clinical QTc trials.
    Glomb P; Ring A
    J Biopharm Stat; 2012; 22(2):387-400. PubMed ID: 22251181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
    Milic M; Bao X; Rizos D; Liu F; Ziegler MG
    Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The joint modeling of drug and positive control effects to estimate sample size and power in crossover "thorough" QT/QTc studies.
    Hosmane B; Locke C; Chiu YL
    J Biopharm Stat; 2013; 23(4):871-80. PubMed ID: 23786591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of baseline ECG collection on the planning, analysis and interpretation of 'thorough' QT trials.
    Sethuraman V; Sun Q
    Pharm Stat; 2009; 8(2):113-24. PubMed ID: 18481273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of ANOVA to estimate inter- and intra-reader variability for a group of readers in thorough QT/QTc studies.
    Natekar M; Mahajan V; Satra A; O'Kelly M; Karnad DR
    Clin Pharmacol Ther; 2008 Mar; 83(3):489-91. PubMed ID: 18183035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bias and variance evaluation of QT interval correction methods.
    Wang Y; Pan G; Balch A
    J Biopharm Stat; 2008; 18(3):427-50. PubMed ID: 18470754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study.
    Charbit B; Alvarez JC; Dasque E; Abe E; Démolis JL; Funck-Brentano C
    Anesthesiology; 2008 Aug; 109(2):206-12. PubMed ID: 18648229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
    Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
    Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revisit the combination validation test of Tsong et al. for thorough QT/QTc clinical trials.
    Sun GG; Quan H
    J Biopharm Stat; 2010 May; 20(3):683-7; author reply 688. PubMed ID: 20358445
    [No Abstract]   [Full Text] [Related]  

  • 38. Sample size of thorough QTc clinical trial adjusted for multiple comparisons.
    Tsong Y; Sun A; Kang SH
    J Biopharm Stat; 2013; 23(1):57-72. PubMed ID: 23331221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A maximum likelihood approach for estimating the QT correction factor using mixed effects model.
    Shah A; Hajian G
    Stat Med; 2003 Jun; 22(11):1901-9. PubMed ID: 12754723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of baseline measurement on the change from baseline in QTc intervals.
    Tian H; Natarajan J
    J Biopharm Stat; 2008; 18(3):542-52. PubMed ID: 18470762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.